Your session is about to expire
← Back to Search
mRNA Vaccine Boosters for COVID-19
Study Summary
This trial will test how well different doses of a new COVID-19 vaccine work in people, as well as how safe it is.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I'm sorry, I cannot provide a summary for this criterion as it appears to be incomplete. Can you please provide more context or information?You are currently experiencing a serious adverse event in another study called mRNA-1273-P301 (COVE) at the time of screening for this study.You have had inflammation of the heart or the sac around the heart within the past two months.You have experienced severe allergic reactions in the past to the vaccine or its ingredients.
- Group 1: Part A.2: mRNA-1273.214 50 μg
- Group 2: Part D: mRNA-1273.213 100 μg
- Group 3: Part E: mRNA-1273.213 100 μg
- Group 4: Part F Cohort 1: mRNA-1273.529 50 μg
- Group 5: Part F Cohort 2: mRNA-1273.529 50 μg and mRNA-1273 50 μg
- Group 6: Part J: mRNA-1273.815 or mRNA-1273.231
- Group 7: Part G: mRNA-1273.214 50 μg
- Group 8: Part H: mRNA-1273.222 50 μg
- Group 9: Part A.1: mRNA-1273.211 50 μg
- Group 10: Part A.1: mRNA-1273.211 100 μg
- Group 11: Part B: mRNA-1273 100 μg
- Group 12: Part C: mRNA-1273.617.2 100 μg
- Group 13: Part C: mRNA-1273.617.2 50 μg
- Group 14: Part D: mRNA-1273.213 50 μg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this medical study taking place in more than one facility within the state?
"Presently, this trial is enrolling patients from 22 clinical sites. Some of these locations include Sacramento, Norfolk and Grand Island. To cut down on travel-related stressors, try to select the location nearest you."
How many people are participating in the research project?
"This specific trial is not enrolling patients at the moment, however this may change in the future. Last updated on November 16th, 2022, this study was originally posted on May 28th, 2021. There are 1119 other trials actively searching for participants with covid-19 and 28 trials for mRNA-1273.211 that are still enrolling patients."
How does mRNA-1273.211 compare to other similar treatments?
"The first study of mRNA-1273.211 took place in 2020 at Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases. There have been a total of 8 completed clinical trials since then, with 28 more currently underway across the globe; many of these are being conducted out of Sacramento, California."
Are people with the relevant medical condition still able to sign up for this experiment?
"The clinical trial in question is not presently seeking participants, as per the information available on clinicaltrials.gov. This specific study was first posted on 5/28/2021 and was last edited on 11/16/2022; however, there are 1147 other clinical trials that are actively recruiting patients right now."
Is this a unique or innovative clinical trial?
"A search of available data reveals that there are 28 ongoing studies for mRNA-1273.211 in 219 cities across 22 countries. The first trial was sponsored by ModernaTX, Inc. and completed its Phase 1 drug approval stage in 2020 after involving 120 patients. In the two years since the initial study, 8 more trials have been conducted."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger